
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Accenture has launched the latest version of its annual study of the biopharmaceutical industry.
Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.
Some highlights from this year’s study include:
For more information, visit the






